Skip to content
Screener

Arrowhead Research ARWR Short-Term Investments

Short-Term Investments at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$1.14B-14.5%
ALN
Alnylam PharmaceuticalsALNY
$1.6B-8.3%
Assembly Biosciences logo
Assembly BiosciencesASMB
$195.48M+189%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$71.52M-5.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$167M-46.4%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$923.36M+33.4%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemMarch 31, 2026September 30, 2025
Cash, cash equivalents and restricted cash$147,531$88,706
Cash at variable interest entity40,986137,842
Accounts receivable15,6856,824
Available-for-sale securities, at fair value and short-term investments1,595,574692,818
Prepaid expenses21,72110,933
Other current assets18,25413,516
Total current assets1,839,751950,639
Property, plant and equipment, net374,822382,515

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's short-term investments?
Arrowhead Research (ARWR) reported short-term investments of $1.6B in Q1 2026.
How has Arrowhead Research's short-term investments changed year-over-year?
Arrowhead Research's short-term investments increased by 75.0% year-over-year, from $911.7M to $1.6B.
What is the long-term trend for Arrowhead Research's short-term investments?
Over 4 years (2021 to 2025), Arrowhead Research's short-term investments has grown at a 87.0% compound annual growth rate (CAGR), from $56.63M to $692.82M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about Arrowhead Research's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude